TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB07150

Activity

Antibacterial Antifungal Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia Antifungipept CAFPdb PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 13-aa standard natural multi-activity (Antibacterial, Antifungal, Hemolysis, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Sequence

FLGALWEVAKSVF

FASTA

>TPDB07150|Antibacterial;Antifungal;Hemolysis;Toxicity|length=13
FLGALWEVAKSVF

Formula C73H107N15O17

Absent Amino Acids RNDCQHIMPTY

Common Amino Acids ALFV

Mass 1466.74

PI 6.94

Basic Residues 1

Acidic Residues 1

Hydrophobic Residues 9

Net Charge -0

Boman Index -2.28

Hydrophobicity 1.208

Aliphatic Index 120.00

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 5500

Absorbance 280nm 374.98

Polar Residues 1

number

2

A

0

R

0

N

0

D

0

C

1

E

0

Q

1

G

0

H

0

I

2

L

1

K

0

M

2

F

0

P

1

S

0

T

1

W

0

Y

2

V

Amino Acid Distribution

A: 2 R: 0 N: 0 D: 0 C: 0 E: 1 Q: 0 G: 1 H: 0 I: 0 L: 2 K: 1 M: 0 F: 2 P: 0 S: 1 T: 0 W: 1 Y: 0 V: 2

Length

13

Formula

C73H107N15O17

Mass

1466.74

PI

6.94

Net Charge

-0

Boman Index

-2.28

Hydrophobicity

1.208

Evidence 1 Activity

Activity

Activity Endpoint MHC

Detail Source Activity Hemolysis

Activity Measurement 1.60 µM

Hemolysis Raw

[Ref.27912176] MHC=1.60µmol/L against human red blood cells

Target

RBC Target human red blood cells

Source & Reference

Database Source Hemolytik PD_Hemolysis

Source DRAMP4

Reference

Eur J Med Chem. 2017 Jan 27 126:456-463.

Other

Source Activity Label	Source Definition
Hemolysis	Hemolytik experimentally validated hemolytic peptide annotation.

Evidence 2 Activity

Activity

Activity Endpoint 0% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 1.6 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

0% Hemolysis | 1.6 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Novel designed VmCT1 analogs with increased antimicrobial activity. | Eur J Med Chem | 2017

Evidence 3 Activity

Activity

Activity Endpoint 75% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 25 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

75% Hemolysis | 25 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Novel designed VmCT1 analogs with increased antimicrobial activity. | Eur J Med Chem | 2017

Evidence 4 Activity

Activity

Activity Endpoint MHC

Detail Source Activity Toxicity

Activity Measurement 1.60 µm

Toxicity Type Hemolytic

Toxicity Raw

Hemolytic_activity: [Ref.27912176] MHC=1.60µmol/L against human red blood cells

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Eur J Med Chem. 2017 Jan 27 126:456-463.

Evidence 5 Hemolysis

Activity

Activity Measurement 1.60 µM

Activity Endpoint MHC

Hemolysis Raw

[Ref.27912176] MHC=1.60µmol/L against human red blood cells

Detail Source Activity Hemolysis

Target

RBC Target human red blood cells

Source & Reference

source PD_Hemolysis

Reference

Eur J Med Chem. 2017 Jan 27 126:456-463.

Source DRAMP4

Database Source PD_Hemolysis